Abstract
UV radiation is the major environmental risk factor for melanoma; protection from exposure is an important primary prevention tool. Skin examinations by physician and patient self-exams are vital secondary prevention tools that stop progression of precursor lesions and early-stage melanomas. Enhancing DNA repair is a promising tactic for reducing UV-related melanoma risk. These strategies/agents require validation in appropriate clinical and preclinical models (Table 3.1). The cholesterol biosynthetic pathway participates in activation of oncogenes, making it a viable target for melanoma prevention despite limitations of epidemiological data supporting the efficacy of statins. These strategies/agents require validation in appropriate clinical and preclinical models (Table 3.1). NSAIDs could have some ability to lower the risk of melanoma. These strategies/agents require validation in appropriate clinical and preclinical models (Table 3.1). Antioxidants, including those derived from dietary agents, have promising activity for reducing UV-induced skin damage and for prevention of melanoma. These strategies/agents require validation in appropriate clinical and preclinical models (Table 3.1). IFN-α reduces phospho-STAT3 in dysplastic nevi, a promising biomarker of melanoma progression.
Original language | English (US) |
---|---|
Title of host publication | Emerging Therapeutics for Melanoma |
Publisher | Future Medicine Ltd. |
Pages | 31-42 |
Number of pages | 12 |
ISBN (Print) | 9781780840321, 9781780841168 |
DOIs | |
State | Published - Jan 1 2012 |
Externally published | Yes |
ASJC Scopus subject areas
- Medicine(all)